VyantBio

Cherry Hill, United States Founded: 1999 • Age: 27 yrs
Developer of drug discovery platform

About VyantBio

VyantBio is a Healthcare company based in Cherry Hill (United States) founded in 1999. VyantBio has raised $10.5 million across 4 funding rounds from investors including National Science Foundation. The company has 25 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is VYANT BIO, INC. Its competitors include Vivodyne, Adapsyn and Parallel Bio; 2 of its 3 listed competitors have raised funding.

Company details

Developer of drug discovery platform. The company has an AnalytiX platform to identify drug candidates, targets, and biomarkers with the help of human biology and machine learning. The company is developing human disease models and drugs for multiple diseases.

  • Headquarters Cherry Hill, United States
  • Employees 25
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website vyantbio.com
  • Social LinkedIn X
  • Legal Name Vyant Bio, Inc.
Key Metrics
  • Annual Revenue
    $666 K (USD)
    -42
    as on Dec 31, 2022
  • Total Equity Funding
    $10.5M (USD)

    in 4 rounds

  • Latest Funding Round
    $5.5M (USD), Series A

    Sep 2016

  • Investors
  • Employee Count
    25

Funding Insights of VyantBio

VyantBio has successfully raised a total of $10.5M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.5 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $10.5M
  • Total Rounds 4
  • Last Round Series A β€” $5.5M
  • First Round $150,000

    (Jul 2007)

  • Investors Count 1

All 4 funding rounds of VyantBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2016$5.5MSeries A––
–
May 2016$5MSeries A––
–
Apr 2009$600,000Grant––
Jul 2007$150,000Grant––
Valuation history

1 investors in total: 1 institutional.

Investors in VyantBio

VyantBio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
A government-backed foundation providing seed-stage investments to support small businesses.
1950nsf.govArlington, United States
Premium access

Investor details for VyantBio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of VyantBio

14 people are tracked at VyantBio (6 in leadership, 6 in board & advisors, 2 in team); the tracked headcount is 25.

NameRoleGroup
Jay Roberts
President & CEOLeadership
Andrew D.C. Lafrence
CFOLeadership
Robert T. Fremeau
Chief Scientific OfficerLeadership
Robert Torka
Director Business Development EuropeLeadership
Melanie Keller
Division Head EuropeLeadership
William Davis
Director of Clinical Sales EastLeadership
John Fletcher
ChairmanBoard & advisors
Geoffrey Harris
DirectorBoard & advisors
Joanna Horobin
DirectorBoard & advisors
Paul Hansen
DirectorBoard & advisors
Howard Mcleod
DirectorBoard & advisors
Ping Yeh
DirectorBoard & advisors
Carol Walling
Clinical Sales SpecialistTeam
Mijanou van der Woude
Site Operations ManagerTeam
Premium access

Complete people profiles for VyantBio

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of VyantBio

3 dated milestones of VyantBio across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded VyantBio is founded.
  2. Funding First funding round of $150K.
  3. Funding Latest funding round, Series A, of $5.5M.

Competitors of VyantBio

VyantBio has 3 listed competitors in our database, 2 of them funded. They include Vivodyne, Adapsyn and Parallel Bio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
vivodyne.com2021Philadelphia, United States$117.69M
Developer of AI-based platform for lab-grown human tissues
adapsyn.com2016Hamilton, United States
Provider of computational tools for bacterial metabolomic and genomic data analysis
parallel.bio2020Cambridge, United States$25.43M6
Limited information available
Premium access

Detailed competitors of VyantBio

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as VyantBio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vyantbio

Premium access

Complete news archive for VyantBio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about VyantBio

VyantBio was founded in 1999 and raised its 1st funding round 8 years after it was founded.

VyantBio is headquartered in Cherry Hill, United States. It is registered at Cherry Hill, New Jersey, United States.

VyantBio is a funded company, having raised a total of $10.5M across 4 funding rounds to date. The company's 1st funding round was a Grant of $150K, raised on Jul 2007.

VyantBio has 25 employees.

Annual revenue of VyantBio is $666K as on Dec 31, 2022.

Developer of drug discovery platform. The company has an AnalytiX platform to identify drug candidates, targets, and biomarkers with the help of human biology and machine learning. The company is developing human disease models and drugs for multiple diseases.

VyantBio's top competitors include Vivodyne, Parallel Bio and Adapsyn.

VyantBio has 1 investor. Key investors include National Science Foundation.

VyantBio operates through Vyant Bio, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available